Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rifabutin-based triple therapy for H. pylori gets high marks

Key clinical point: The triple-drug combo was recently approved by the FDA as the first new treatment for Helicobacter pylori since 1997.

Major finding: The H. pylori eradication rate was 84% with rifabutin-based triple therapy and 58% with high-dose dual therapy with amoxicillin plus omeprazole.

Study details: This was a phase 3, double-blind, multicenter, active comparator–controlled randomized trial including 455 participants with H. pylori infection.

Disclosures: The presenter reported having no financial conflicts regarding the study, sponsored by RedHill Biopharma.

Citation:

Graham DY. ACG 2019, Abstract 63.